

USER INFORMATION
INJESOL KDP
Potassium Dihydrogen Phosphate 13.6% w/v Concentrated Injection BP
Sterile and Non-Pyrogenic

Composition:

Each 10 mL solution contains: Potassium Dihydrogen Phosphate 1.361 g
Each 10 mL solution contains: K⁺ 10 mmol
PO₄³⁻ 10 mmol
H⁺ 20 mmol

Product Description:

INJESOL KDP (before and after dilution) is a clear and colourless solution practically free from any visible particles.

Pharmacology:

Pharmacodynamics:

The majority (80%) of the body's Phosphate is found as Calcium Phosphate in the skeleton, where it gives rigidity to the bone. The remainder is found in soft tissues. Phosphate is the principal anion of intracellular fluid. In body fluids, Phosphate is present mainly as divalent Hydrogen Phosphate (HPO₄²⁻) ions (approximately 80%) and monovalent Dihydrogen Phosphate (H₂PO₄⁻) ions (approximately 20%). Apart from its essential role in bone structure, Phosphate is also important in many metabolic and enzymatic pathways. It is involved in energy storage and transfer, the utilization of B-complex vitamins, the buffering of body fluids, and in the renal excretion of Hydrogen ions. Hypophosphataemia may arise from a variety of causes including primary hyperparathyroidism, Vitamin D deficiency, X-linked familial hypophosphataemia, alcoholism, hepatic failure and septicaemia. The symptoms of hypophosphataemia include muscle weakness, paraesthesia, convulsions, cardiomyopathy, respiratory failure and haematological abnormalities. Prolonged hypophosphataemia may result in rickets or osteomalacia.

Pharmacokinetics:

The normal concentration range of Phosphate in plasma is 0.8 to 1.5 mmol/L.

Phosphate is primarily excreted in the urine. Over 90% of plasma Phosphate is filtered in the kidneys with the majority being reabsorbed in the proximal tubule. Parathyroid hormone decreases the tubular reabsorption of Phosphate, thereby increasing urinary excretion. In addition, serum Phosphate levels are inversely related to serum Calcium levels and to renal metabolism of Vitamin D. A decrease in serum Calcium concentration will result in increased serum Phosphate levels.

Indication:

Treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/L) and other degrees of hypophosphataemia when oral therapy is not possible. The cause of hypophosphataemia should be identified and treated.

Recommended Dosage:

For the treatment of severe hypophosphataemia, the following doses are suggested.

Adults: up to 10 mmol Phosphate administered over 12 hours. The dose may be repeated at 12 hour intervals until serum Phosphate exceeds 0.3 mmol/L.

Children: 0.15 - 0.33 mmol/kg administered over 6 hours. The dose may be repeated at 6 hour intervals until serum Phosphate exceeds 0.6 mmol/L. The dose should not exceed the maximum recommended adult dose. The rate of infusion should not exceed 0.2 mmol/kg/h.

Method of Administration

INJESOL KDP is administered by slow intravenous infusion. The injection must be diluted before use.

Dilution: **INJESOL KDP** must be diluted before use. The drug can be given in 0.9% Sodium Chloride or 5% Glucose solution. It should be administered by slow infusion to avoid Phosphate intoxication.

Monitoring: Serum Sodium, Potassium, Phosphate and Calcium concentrations and renal function should be monitored every 12 to 24 hours during therapy. Conversion to oral phosphate therapy should occur as soon as possible.

Dosage Adjustments

Renal Impairment: dose should be reduced. Use of Phosphates in severe renal impairment is contraindicated.

Route of Administration : Intravenous (IV)

Contraindications:

INJESOL KDP is contraindicated in:

- Patients with severe renal function impairment (less than 30% normal) since there is an increased risk of hyperphosphataemia in these patients.
- Patients with hyperphosphataemia, since Phosphate therapy will exacerbate the condition.
- Patients with hypocalcaemia due to the close relationship between hypocalcaemia and hyperphosphataemia.
- Patients with hyperkalaemia, since the Potassium in the injection may exacerbate the condition.
- Addison's disease since there is an increased risk of hyperkalaemia in these patients.
- Urolithiasis (Magnesium Ammonium Phosphate type, infected) since it may exacerbate the condition.
- Renal impairment with oliguria and azotaemia.
- Ventricular fibrillation.
- Hyperadrenalism associated with adrenogenital syndrome.
- Extensive tissue breakdown as in severe burns.
- Acute dehydration.
- Heat cramps.
- Increased sensitivity to Potassium administration as in adynamia episodica hereditaria or congenital paramyotonia.

Warnings and Precautions :

INJESOL KDP MUST NOT BE INJECTED UNDILUTED. DIRECT INJECTION WITHOUT APPROPRIATE DILUTION MAY CAUSE INSTANT DEATH. FOR SLOW I.V. INFUSION ONLY. NOT FOR I.V. BOLUS.

Potassium

The use of Potassium salts in patients with chronic renal disease, adrenal insufficiency or any other condition which impairs Potassium excretion, requires particularly careful monitoring of the serum Potassium concentration and appropriate dosage adjustment. Potassium should be used with caution in diseases associated with heart block since increased serum Potassium may increase the degree of block.

Hyperkalaemia: Monobasic Potassium Phosphates should be avoided in patients with hyperkalaemia. Sodium Phosphates may be substituted.

Phosphate

Phosphate should be administered with caution in conditions where high Phosphate levels may be encountered, such as hypoparathyroidism, chronic renal disease, rhabdomyolysis, acute dehydration, pancreatitis, severe renal insufficiency and extensive tissue damage (such as severe burns).

Phosphate should be administered with caution in conditions where low Calcium levels may be encountered, such as hypoparathyroidism, osteomalacia, chronic renal disease, acute pancreatitis, rhabdomyolysis, rickets, myotonia congenita, and heart disease (particularly in digitalised patients) since these conditions may be exacerbated by the Potassium in the injection. The cause of hypophosphataemia should be identified and treated. Caution should be used where patients may be hypocalcaemic. Serum electrolyte and especially Phosphate levels in the body and renal function should be monitored during treatment. Phosphates should not be administered to patients with severely impaired renal function. Aluminium, Calcium, or Magnesium salts should not be administered concomitantly with Phosphates as they bind Phosphate thus impairing its absorption from the gastro-intestinal tract.

Caution:

INJESOL KDP must be used immediately after dilution. Single dose container. Discard all unused contents. Do not use if the solution is discoloured and leakage is detected.

Warnings

In patients with impaired mechanisms for excreting Potassium, administration of Potassium salts can produce hyperkalaemia and cardiac arrest. This is an important concern in patients given IV Potassium. Potentially fatal hyperkalaemia can develop rapidly and be asymptomatic. In patients being given Potassium especially by IV, monitoring of serum electrolytes, the ECG and the patient's clinical status is indicated.

Effects on laboratory tests

Saturation of bone binding sites by Phosphate ions may cause decreased bone uptake of technetium Tc^{99m} labelled contrast agents in bone imaging.

Interactions with Other Medicaments:

Angiotensin converting enzyme (ACE) inhibitors:

Concurrent use with **INJESOL KDP** may result in hyperkalaemia, especially in patients with renal impairment.

Calcium containing medicines:

Concurrent use of **INJESOL KDP** and Calcium containing medicines may increase the risk of deposition of Calcium in soft tissues.

Digitalis glycosides:

The administration of **INJESOL KDP** in digitalised patients with severe or complete heart block may result in hyperkalaemia. **Potassium sparing diuretics:** Concurrent use with **INJESOL KDP** may result in hyperkalaemia, especially in patients with renal impairment.

Non-steroidal anti-inflammatory agents (NSAIDs):

Concurrent use with **INJESOL KDP** may result in hyperkalaemia, especially in patients with renal impairment.

Phosphate containing medicines:

Concurrent use with **INJESOL KDP** may result in hyperphosphataemia, especially in patients with impaired renal function.

Potassium containing medicines:

Concurrent use with **INJESOL KDP** may result in hyperkalaemia, especially in patients with renal impairment.

Salicylates:

Concurrent use with **INJESOL KDP** may increase the serum concentration of Salicylates, since Salicylate excretion is decreased in acidified urine. This may result in toxic salicylate concentrations when Phosphate is administered to patients already stabilized on Salicylates.

Statement on usage during pregnancy and lactation:**Pregnancy:**

Animal reproduction studies have not been conducted with this product. It is not known whether this product can adversely affect the foetus when administered to a pregnant woman. Therefore, **INJESOL KDP** is not recommended for use during pregnancy.

Lactation:

It is not known whether Phosphates are excreted into breast milk, therefore **INJESOL KDP** is not recommended for use during lactation.

Adverse Effects/Undesirable Effects:**Cardiovascular**

Uncommon: hypotension

Rare: myocardial infarction

Endocrine/Metabolic

Uncommon: fluid retention as indicated by swelling of feet or lower legs or weight gain; hyperkalaemia leading to confusion, tiredness or weakness, irregular or slow heart rate, numbness or tingling around lips, hands or feet, unexplained anxiety, weakness or heaviness of legs, shortness of breath or troubled breathing; hypernatraemia leading to confusion, tiredness or weakness, convulsions, oliguria or decreased frequency of micturition, tachycardia, headache or dizziness, increased thirst; hyperphosphataemia, hypocalcaemia or hypomagnesaemia leading to convulsions, muscle cramps, numbness, tingling, pain or weakness in hands or feet, shortness of breath or troubled breathing, tremor; extraskeletal calcification as nephrocalcinosis has been reported in children with hypophosphataemic rickets treated with Phosphate supplements.

Genitourinary

Rare: acute renal failure

The symptoms and signs of Potassium intoxication include paraesthesia of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, fall in blood pressure, cardiac arrhythmias and heart block. Hyperkalaemia may exhibit the following ECG abnormalities: disappearance of the P-wave, widening and slurring of QRS complex, changes of the S-T segment, tall-peaked T-waves. Nausea, vomiting, diarrhoea and abdominal discomfort have been reported.

Treatment of adverse effects involves withdrawal of Phosphate, general supportive measures, and correction of serum-electrolyte concentrations, especially Calcium.

Overdose and Treatment:**Phosphate**

Excessive administration of Phosphate, particularly by the intravenous route, may cause hyperphosphataemia but this rarely occurs unless there is renal failure. Hyperphosphataemia may also occur in the presence of acidosis, acromegaly, haemolysis, hypoparathyroidism, tissue destruction, or vitamin D toxicity. Symptoms associated with hyperphosphataemia include muscle weakness, paraesthesia, convulsions, cardiomyopathy, respiratory failure and haematological abnormalities.

Hyperphosphataemia leads in turn to hypocalcaemia, which may be severe, and to ectopic calcification. Secondary hyperparathyroidism develops in the presence of renal failure.

Crystalline deposition may occur in important structures including blood vessels of the eye, lung, heart and kidney. Fatal alveolar diffusion block has occurred, the risk being greater if the patient is alkalotic.

Treatment

Treatment of overdose involves the following measures:

- Immediate cessation of Phosphate therapy.
- Correction of serum electrolyte concentrations, especially Calcium.
- General supportive treatment.

Potassium

If excretory mechanisms are impaired or if IV Potassium is administered too rapidly, potentially fatal hyperkalaemia can result. However, hyperkalaemia is usually asymptomatic and may be manifested only by an increased serum Potassium concentration and characteristic ECG changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest. Should any of these manifestations occur, discontinue Potassium administration immediately.

Treatment

If hyperkalaemia develops, the following measures should be considered: elimination of foods and medications containing Potassium and of Potassium-sparing diuretics; IV administration of 300 to 500 mL/hour of 10% Glucose solution containing 10 to 20 units of insulin/1000 mL; correction of acidosis, if present, with IV Sodium Bicarbonate; use of exchange resins, haemodialysis, or peritoneal dialysis; in presence of life-threatening cardiac arrhythmias, IV administration of 10 to 50 mL Calcium Gluconate 10% over 5 minutes. Continuous ECG monitoring is mandatory.

In treating hyperkalaemia in digitalised patients, too rapid a lowering of the serum Potassium concentration can produce digitalis toxicity.

Effects on Ability to Drive and Use Machine:

No data available.

Incompatibilities:

Phosphates are reported to be incompatible with Calcium or Magnesium containing solutions. Admixture will lead to precipitates being formed in the solution. Solutions containing other cations such as Iron and Aluminium may also precipitate when added to the products.

Storage Conditions:

Before Dilution: Do not store above 30°C

After Dilution: Product should not be used undiluted. Once product is diluted, it should be used immediately and storage should not be more than 6 hours at 30°C. This product also can be stored in refrigerator between 2 - 8°C not exceeding 24 hours.

Shelf Life:

3 years from manufacturing date in the proposed storage condition. The solution should be used immediately after dilution. Do not use after expiry.


Dosage forms and packaging available:

10 mL X 20 LDPE plastic ampoules per box


Manufacturer/Product Registration Holder:

AIN MEDICARE SDN. BHD.


Lot 4933, 4934 & PT2464, Jalan 6/44, Kaw. Perindustrian Pengkalan Chepa 2, 16100 Kota Bharu, Kelantan, MALAYSIA

HANDLING INSTRUCTION**AIN MEDICARE INJECTION FLUID IN POLYETHYLENE (PE) AMPOULE**


Detach ampoule along parting line



Twist off tab



Attach luer lock syringe, luer slip syringe or hypodermic needle vertically to the ampoule.



Draw out injection fluid using luer lock syringe, luer slip syringe or hypodermic needle. Ensure the connection is tightly secured for the liquid.